HIV/AIDS Therapy
Switching from a protease inhibitor to nevirapine maintains viral control
Published in AIDS Weekly, November 28th, 2005
In a recent study, researchers in Spain conducted a study to "assess the antiviral efficacy and safety of switching from a protease inhibitor (PI) to nevirapine in patients with long-term HIV-1 RNA suppression on PI-containing regimens, and to assess its influence in the adherence to treatment."
"In an open-label multicenter study, 160 HIV-infected patients with undetectable viral load for at least 6 months on a PI-containing regimen were randomized to either continue with their PI regimen (n=79) or replace PI with nevirapine (n=8 1).
"Clinical assessment...
Want to see the full article?
We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of AIDS Weekly
Source: AIDS Weekly (2005-11-28)
More Articles from AIDS Weekly
- HIV/AIDS Pathogenesis
HIV Tat alters circadian rhythms through the light entrainment pathway - HIV/AIDS Pathogenesis
HIV-1 Tat selectively enhances CXCR4 and inhibits CCR5 expression in megakaryocytes - HIV/AIDS Pathogenesis
HIV-1 buffers effects of detrimental variations in viral and cellular functions - HIV/AIDS Transmission
Vertical transmission of HIV during gestation determined to be frequent - Addiction Medicine
New findings in the area of addiction medicine described - Cervical Cancer
Researchers' work adds to cervical cancer body of knowledge - More from this issue of AIDS Weekly
NewsRx is Social
Follow us on your favorite social network by clicking on a button below:
Top Medical Newsletters
Awards
Best Health/Healthcare Content, 2012
Best Health/Healthcare Content, 2011
Best e-Business Site, 2010
Best e-Business Site, 2009
Best e-Business Site, 2008
Best e-Business Site, 2007
Best e-Business Site, 2006
Best Healthcare Content, 2005
Best Overall Internet Site, 2005
Best Interactive Site, 2005
Facts & Stats
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.
- Google 2010 PageRank: #2 Among Top Health News and Media Publications
- Google 2010 PageRank: #2 Among Top Science Publications in Biology/Physiology
- Google 2010 PageRank: #2 Among Top News and Media for the Business of Pharmaceuticals
- Amazon's Alexa 2010 PageRank: #2 News and Media Site for the Pharmaceutical Industry
